(18)F NaF PET/CT in the Assessment of Metastatic Bone Disease: Comparison with Specific PET Tracers.
The skeletal system is the third most common site of metastases after the lungs and liver, and 80% of all reported metastatic bone disease is in patients with breast and prostate cancer. At present there are an unprecedented number of novel molecular imaging agents potentially available for the assessment of bone metastases in different cancer. This review assesses the role of PET in the imaging of skeletal metastases, focusing on the specific PET tracers (fluorodeoxyglucose, choline derivatives, and so forth), in comparison with (18)F NaF as a nonspecific bone-seeking PET agent.